Carl H Sadowsky1, Joseph L Micca1, George T Grossberg1, Drew M Velting1. 1. Division of Neurology, Nova Southeastern University, Fort Lauderdale, and Premiere Research Institute, Palm Beach Neurology, West Palm Beach, Florida (Dr Sadowsky); Private Practice, Marietta, Georgia (Dr Micca); Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, Missouri (Dr Grossberg); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Velting).
Abstract
OBJECTIVE: To discuss the pharmacology, mechanism of action, and chemical properties of the cholinesterase inhibitor (ChEI) rivastigmine; to provide a rationale for transdermal delivery and supportive clinical data, along with practical guidance on rivastigmine patch use in Alzheimer's disease and Parkinson's disease dementia. DATA SOURCES: Pivotal studies of rivastigmine capsules and patch were identified using PubMed and the rivastigmine US prescribing information. PubMed searches were performed in 2013 using rivastigmine as a keyword. STUDY SELECTION: English-language articles related to rivastigmine considered of relevance to primary care physicians were included. DATA SYNTHESIS: Pharmacologic differences exist between rivastigmine and ChEIs. Clinical studies demonstrate symptomatic efficacy of oral rivastigmine across all stages of Alzheimer's disease and mild-to-moderate Parkinson's disease dementia. However, gastrointestinal adverse events limit access to optimal therapeutic doses. Strategies that lower maximum plasma concentrations (Cmax) and prolong time to Cmax, ie, transdermal delivery, may improve tolerability. Clinical registration studies have demonstrated improved tolerability of rivastigmine 9.5-mg/24-h patch versus 6-mg twice-daily capsules in mild-to-moderate Alzheimer's disease, and a positive benefit-risk profile of 13.3-mg/24-h versus 9.5-mg/24-h patch in patients needing enhanced efficacy. Clinical data comparing 13.3-mg/24-h versus 4.6-mg/24-h patch in severe Alzheimer's disease demonstrated efficacy on cognition and activities of daily living. These data led to approval of rivastigmine patch in severe Alzheimer's disease. Transdermal delivery also has practical advantages, including simple, once-daily administration and a visual indicator of compliance. Potential application site reactions can be minimized and need not be a barrier to treatment. CONCLUSIONS: In addition to practical advantages, rivastigmine patch may improve clinical outcomes throughout the course of Alzheimer's disease by providing access to high-dose efficacy without compromising tolerability.
OBJECTIVE: To discuss the pharmacology, mechanism of action, and chemical properties of the cholinesterase inhibitor (ChEI) rivastigmine; to provide a rationale for transdermal delivery and supportive clinical data, along with practical guidance on rivastigmine patch use in Alzheimer's disease and Parkinson's disease dementia. DATA SOURCES: Pivotal studies of rivastigmine capsules and patch were identified using PubMed and the rivastigmine US prescribing information. PubMed searches were performed in 2013 using rivastigmine as a keyword. STUDY SELECTION: English-language articles related to rivastigmine considered of relevance to primary care physicians were included. DATA SYNTHESIS: Pharmacologic differences exist between rivastigmine and ChEIs. Clinical studies demonstrate symptomatic efficacy of oral rivastigmine across all stages of Alzheimer's disease and mild-to-moderate Parkinson's disease dementia. However, gastrointestinal adverse events limit access to optimal therapeutic doses. Strategies that lower maximum plasma concentrations (Cmax) and prolong time to Cmax, ie, transdermal delivery, may improve tolerability. Clinical registration studies have demonstrated improved tolerability of rivastigmine 9.5-mg/24-h patch versus 6-mg twice-daily capsules in mild-to-moderate Alzheimer's disease, and a positive benefit-risk profile of 13.3-mg/24-h versus 9.5-mg/24-h patch in patients needing enhanced efficacy. Clinical data comparing 13.3-mg/24-h versus 4.6-mg/24-h patch in severe Alzheimer's disease demonstrated efficacy on cognition and activities of daily living. These data led to approval of rivastigmine patch in severe Alzheimer's disease. Transdermal delivery also has practical advantages, including simple, once-daily administration and a visual indicator of compliance. Potential application site reactions can be minimized and need not be a barrier to treatment. CONCLUSIONS: In addition to practical advantages, rivastigmine patch may improve clinical outcomes throughout the course of Alzheimer's disease by providing access to high-dose efficacy without compromising tolerability.
Authors: Bengt Winblad; Ariane K Kawata; Kathleen M Beusterien; Simu K Thomas; Anders Wimo; Roger Lane; Howard Fillit; Rafael Blesa Journal: Int J Geriatr Psychiatry Date: 2007-05 Impact factor: 3.485
Authors: G Lefèvre; G Sedek; S S Jhee; M T Leibowitz; H-La Huang; A Enz; S Maton; L Ereshefsky; F Pommier; H Schmidli; S Appel-Dingemanse Journal: Clin Pharmacol Ther Date: 2007-05-23 Impact factor: 6.875
Authors: N R Cutler; R J Polinsky; J J Sramek; A Enz; S S Jhee; L Mancione; J Hourani; P Zolnouni Journal: Acta Neurol Scand Date: 1998-04 Impact factor: 3.209
Authors: Murat Emre; Werner Poewe; Peter Paul De Deyn; Paolo Barone; Jaime Kulisevsky; Emmanuelle Pourcher; Teus van Laar; Alexander Storch; Federico Micheli; David Burn; Frank Durif; Rajesh Pahwa; Francesca Callegari; Nadia Tenenbaum; Christine Strohmaier Journal: Clin Neuropharmacol Date: 2014 Jan-Feb Impact factor: 1.592
Authors: Martin R Farlow; George T Grossberg; Carl H Sadowsky; Xiangyi Meng; Monique Somogyi Journal: CNS Neurosci Ther Date: 2013-08-07 Impact factor: 5.243
Authors: Tânia M T Guimarães; Tânia Moniz; Cláudia Nunes; Maya Margaritova Zaharieva; Mila Kaleva; Krassimira Yoncheva; Hristo Najdenski; Sofia A Costa Lima; Salette Reis Journal: Pharmaceutics Date: 2022-03-30 Impact factor: 6.525
Authors: Marta Goschorska; Izabela Gutowska; Irena Baranowska-Bosiacka; Katarzyna Piotrowska; Emilia Metryka; Krzysztof Safranow; Dariusz Chlubek Journal: Int J Environ Res Public Health Date: 2018-12-20 Impact factor: 3.390
Authors: Jose A Muñoz-Moreno; Anna Prats; José Moltó; Maite Garolera; Núria Pérez-Álvarez; Crisanto Díez-Quevedo; Cristina Miranda; Carmina R Fumaz; Maria J Ferrer; Bonaventura Clotet Journal: PLoS One Date: 2017-08-30 Impact factor: 3.240